search
Back to results

Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Primary Purpose

Cognitive Deficits in Schizophrenia

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
ABT-288 Low Dose
Placebo
ABT-288 High Dose
Sponsored by
AbbVie (prior sponsor, Abbott)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cognitive Deficits in Schizophrenia

Eligibility Criteria

20 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Has current DSM-IV-TR diagnosis of schizophrenia confirmed by the Mini-International Neuropsychiatric Interview.
  • Is clinically stable while receiving antipsychotic therapy with one or two atypical antipsychotic medications: lack of hospitalizations from 4 months of Initial Screening Visit; taking same antipsychotic medication(s) for at least 8 weeks prior to the Day -1 visit; core positive symptoms of PANSS no worse than moderate in severity throughout Screening Period of at least 4 weeks.
  • Has been diagnosed with or treated for schizophrenia for at least 2 years prior to Initial Screening Visit.
  • Has had continuity in psychiatric care (e.g., mental health system, clinic or physician) for at least 6 months prior to Initial Screening Visit.
  • Has an identified responsible contact person (e.g., family member, social worker, case worker, or nurse) that can provide support to the subject and ensure compliance with protocol requirements.

Exclusion Criteria:

  • Has valid current or past diagnosis of schizoaffective disorder, bipolar disorder, manic episode, dementia, posttraumatic stress disorder, obsessive compulsive disorder, or a current major depressive episode.
  • Has history of substance abuse (excluding nicotine or tobacco products) or alcohol abuse within 6 months prior to Screening Visit; has a substance dependence disorder (excluding nicotine or tobacco products) that has not been remitted for at least 1 year prior to Initial Screening Visit.
  • Is taking any medication for extrapyramidal symptoms at any time from the Initial Screening Visit until the Day -1 Visit.
  • Is taking any antidepressant that is excluded, including tricyclic antidepressants and monoamine oxidase inhibitors, at any time from 8 weeks prior to the Day -1 Visit.
  • Has significant suicidal ideation at Initial Screening Visit.
  • Has had a suicide attempt within 1 year prior to the Day -1 Visit.
  • Has participated in another trial utilizing the MATRICS Consensus Cognitive Battery (MCCB) or UCSD Performance-Based Skills Assessment (UPSA) (any version) within 6 months prior to Initial Screening Visit.
  • Is currently enrolled in any form of cognitive remediation training.

Sites / Locations

  • Site Reference ID/Investigator# 21662
  • Site Reference ID/Investigator# 21683
  • Site Reference ID/Investigator# 21581
  • Site Reference ID/Investigator# 45310
  • Site Reference ID/Investigator# 26400
  • Site Reference ID/Investigator# 21584
  • Site Reference ID/Investigator# 45312
  • Site Reference ID/Investigator# 45309
  • Site Reference ID/Investigator# 46603
  • Site Reference ID/Investigator# 21681
  • Site Reference ID/Investigator# 26397
  • Site Reference ID/Investigator# 21761
  • Site Reference ID/Investigator# 21591
  • Site Reference ID/Investigator# 26409
  • Site Reference ID/Investigator# 21588
  • Site Reference ID/Investigator# 21589
  • Site Reference ID/Investigator# 26407
  • Site Reference ID/Investigator# 21601
  • Site Reference ID/Investigator# 26399
  • Site Reference ID/Investigator# 21590
  • Site Reference ID/Investigator# 21582
  • Site Reference ID/Investigator# 26406
  • Site Reference ID/Investigator# 26402
  • Site Reference ID/Investigator# 27502

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

ABT-288 Dose 1

ABT-288 Dose 2

Sugar Pill

Arm Description

low dose of ABT-288

high dose of ABT-288

inactive substance

Outcomes

Primary Outcome Measures

Cognition: MCCB

Secondary Outcome Measures

Functioning: UPSA-2
Cognition: CANTAB
Symptom Severity: PANSS, NSA-16, CGI-S

Full Information

First Posted
February 26, 2010
Last Updated
June 1, 2018
Sponsor
AbbVie (prior sponsor, Abbott)
search

1. Study Identification

Unique Protocol Identification Number
NCT01077700
Brief Title
Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-288 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Study Type
Interventional

2. Study Status

Record Verification Date
January 2013
Overall Recruitment Status
Completed
Study Start Date
March 2010 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
July 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AbbVie (prior sponsor, Abbott)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is an efficacy and safety study evaluating an experimental treatment for cognitive deficits in adults with schizophrenia.
Detailed Description
This is a Phase 2 study designed to evaluate the efficacy and safety of ABT-288 in approximately 210 adults with schizophrenia. Subjects will be randomized to one of three treatment groups (ABT-288 Dose 1, ABT-288 Dose 2 or placebo) for a 12-week Treatment Period. The purpose of this research study is to find out whether ABT-288 compared to placebo can improve cognition and what side effects ABT 288 may cause. Cognition is the way a person thinks, and it includes abilities like paying attention, focusing, remembering things, and solving problems. Acronyms listed in the Outcomes and/or Eligibility sections for this study are defined below: MCCB: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery UPSA-2: University of California at San Diego (UCSD) Performance-Based Skills Assessment-2 CANTAB: Cambridge Neuropsychological Test Automated Battery PANSS: Positive and Negative Syndrome Scale NSA-16: Negative Symptom Assessment-16 CGI-S: Clinical Global Impression - Severity

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cognitive Deficits in Schizophrenia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
214 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ABT-288 Dose 1
Arm Type
Experimental
Arm Description
low dose of ABT-288
Arm Title
ABT-288 Dose 2
Arm Type
Experimental
Arm Description
high dose of ABT-288
Arm Title
Sugar Pill
Arm Type
Placebo Comparator
Arm Description
inactive substance
Intervention Type
Drug
Intervention Name(s)
ABT-288 Low Dose
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
inactive substance
Intervention Type
Drug
Intervention Name(s)
ABT-288 High Dose
Primary Outcome Measure Information:
Title
Cognition: MCCB
Time Frame
Measurements from screening period through 12-week treatment period
Secondary Outcome Measure Information:
Title
Functioning: UPSA-2
Time Frame
Measurements from screening period through 12-week treatment period
Title
Cognition: CANTAB
Time Frame
Measurements from screening period through 12-week treatment period
Title
Symptom Severity: PANSS, NSA-16, CGI-S
Time Frame
Measurements from screening period through 12-week treatment period

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Has current DSM-IV-TR diagnosis of schizophrenia confirmed by the Mini-International Neuropsychiatric Interview. Is clinically stable while receiving antipsychotic therapy with one or two atypical antipsychotic medications: lack of hospitalizations from 4 months of Initial Screening Visit; taking same antipsychotic medication(s) for at least 8 weeks prior to the Day -1 visit; core positive symptoms of PANSS no worse than moderate in severity throughout Screening Period of at least 4 weeks. Has been diagnosed with or treated for schizophrenia for at least 2 years prior to Initial Screening Visit. Has had continuity in psychiatric care (e.g., mental health system, clinic or physician) for at least 6 months prior to Initial Screening Visit. Has an identified responsible contact person (e.g., family member, social worker, case worker, or nurse) that can provide support to the subject and ensure compliance with protocol requirements. Exclusion Criteria: Has valid current or past diagnosis of schizoaffective disorder, bipolar disorder, manic episode, dementia, posttraumatic stress disorder, obsessive compulsive disorder, or a current major depressive episode. Has history of substance abuse (excluding nicotine or tobacco products) or alcohol abuse within 6 months prior to Screening Visit; has a substance dependence disorder (excluding nicotine or tobacco products) that has not been remitted for at least 1 year prior to Initial Screening Visit. Is taking any medication for extrapyramidal symptoms at any time from the Initial Screening Visit until the Day -1 Visit. Is taking any antidepressant that is excluded, including tricyclic antidepressants and monoamine oxidase inhibitors, at any time from 8 weeks prior to the Day -1 Visit. Has significant suicidal ideation at Initial Screening Visit. Has had a suicide attempt within 1 year prior to the Day -1 Visit. Has participated in another trial utilizing the MATRICS Consensus Cognitive Battery (MCCB) or UCSD Performance-Based Skills Assessment (UPSA) (any version) within 6 months prior to Initial Screening Visit. Is currently enrolled in any form of cognitive remediation training.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
George Haig, PharmD
Organizational Affiliation
AbbVie
Official's Role
Study Director
Facility Information:
Facility Name
Site Reference ID/Investigator# 21662
City
Anaheim
State/Province
California
ZIP/Postal Code
92804
Country
United States
Facility Name
Site Reference ID/Investigator# 21683
City
Garden Grove
State/Province
California
ZIP/Postal Code
92845
Country
United States
Facility Name
Site Reference ID/Investigator# 21581
City
National City
State/Province
California
ZIP/Postal Code
91950
Country
United States
Facility Name
Site Reference ID/Investigator# 45310
City
Norwalk
State/Province
California
ZIP/Postal Code
90650
Country
United States
Facility Name
Site Reference ID/Investigator# 26400
City
Pasadena
State/Province
California
ZIP/Postal Code
91106
Country
United States
Facility Name
Site Reference ID/Investigator# 21584
City
Pico Rivera
State/Province
California
ZIP/Postal Code
90660
Country
United States
Facility Name
Site Reference ID/Investigator# 45312
City
Riverside
State/Province
California
ZIP/Postal Code
92506
Country
United States
Facility Name
Site Reference ID/Investigator# 45309
City
San Diego
State/Province
California
ZIP/Postal Code
92128
Country
United States
Facility Name
Site Reference ID/Investigator# 46603
City
Plantation
State/Province
Florida
ZIP/Postal Code
33317
Country
United States
Facility Name
Site Reference ID/Investigator# 21681
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60640
Country
United States
Facility Name
Site Reference ID/Investigator# 26397
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71104-2136
Country
United States
Facility Name
Site Reference ID/Investigator# 21761
City
Pittsfield
State/Province
Massachusetts
ZIP/Postal Code
01201
Country
United States
Facility Name
Site Reference ID/Investigator# 21591
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63139
Country
United States
Facility Name
Site Reference ID/Investigator# 26409
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11235
Country
United States
Facility Name
Site Reference ID/Investigator# 21588
City
Cedarhurst
State/Province
New York
ZIP/Postal Code
11516
Country
United States
Facility Name
Site Reference ID/Investigator# 21589
City
Dayton
State/Province
Ohio
ZIP/Postal Code
45417
Country
United States
Facility Name
Site Reference ID/Investigator# 26407
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73103
Country
United States
Facility Name
Site Reference ID/Investigator# 21601
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19131
Country
United States
Facility Name
Site Reference ID/Investigator# 26399
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29407
Country
United States
Facility Name
Site Reference ID/Investigator# 21590
City
Austin
State/Province
Texas
ZIP/Postal Code
78731
Country
United States
Facility Name
Site Reference ID/Investigator# 21582
City
Austin
State/Province
Texas
ZIP/Postal Code
78754
Country
United States
Facility Name
Site Reference ID/Investigator# 26406
City
DeSoto
State/Province
Texas
ZIP/Postal Code
75115
Country
United States
Facility Name
Site Reference ID/Investigator# 26402
City
Houston
State/Province
Texas
ZIP/Postal Code
77008
Country
United States
Facility Name
Site Reference ID/Investigator# 27502
City
Bellevue
State/Province
Washington
ZIP/Postal Code
98007
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
24516190
Citation
Haig GM, Bain E, Robieson W, Othman AA, Baker J, Lenz RA. A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia. Schizophr Bull. 2014 Nov;40(6):1433-42. doi: 10.1093/schbul/sbt240. Epub 2014 Feb 10.
Results Reference
result
PubMed Identifier
28433500
Citation
Georgiades A, Davis VG, Atkins AS, Khan A, Walker TW, Loebel A, Haig G, Hilt DC, Dunayevich E, Umbricht D, Sand M, Keefe RSE. Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients. Schizophr Res. 2017 Dec;190:172-179. doi: 10.1016/j.schres.2017.03.040. Epub 2017 Apr 20.
Results Reference
derived

Learn more about this trial

Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia

We'll reach out to this number within 24 hrs